PMID: 8944748Nov 11, 1996Paper

Human apolipoprotein A-II inhibits the formation of pre-beta high density lipoproteins

Biochimica Et Biophysica Acta
L CalabresiG Franceschini

Abstract

The role of human apolipoprotein A-II (apoA-II) in the remodeling of human high density lipoproteins (HDL) was investigated during incubation of native and reduced-carboxamidomethylated (RCM) HDL3 with a lipoprotein-depleted plasma fraction (LPDP) in the presence of triglyceride-rich particles (TGRP) isolated from Intralipid. Reduction-carboxamidomethylation of HDL3 entirely converts the disulfide-linked apoA-II dimers into monomers, without affecting the structure, composition and particle size distribution of HDL3. Following incubation with LPDP and TGRP, unmodified HDL3 are mainly converted into large, HDL2 particles (diameter: 9.90 +/- 0.07 nm), enriched in triglycerides and depleted of cholesteryl esters. RCM-HDL3 are converted into both large HDL2 (9.86 +/- 0.07 nm) and small (7.53 +/- 0.06 nm) HDL3. The small products are protein-rich and cholesterol-poor, and consist of two different particles: a component with pre-beta mobility, containing only apoA-I, and a component with alpha mobility, containing both apoA-I and apoA-II. Kinetic studies suggest that a two-step process is involved in the formation of small, pre beta-HDL3, by which changes in lipid composition cause alterations in lipoprotein structure/stability, favo...Continue Reading

References

Aug 15, 1977·Clinica Chimica Acta; International Journal of Clinical Chemistry·M TakayamaI Tanimizu
Mar 4, 1992·Biochimica Et Biophysica Acta·L CalabresiG Franceschini
Jan 1, 1986·Methods in Enzymology·T M Forte, R W Nordhausen
Aug 22, 1989·Biochimica Et Biophysica Acta·J A IbdahM C Phillips
Nov 9, 1989·The New England Journal of Medicine·D J Gordon, B M Rifkind
Nov 1, 1987·Atherosclerosis·P PuchoisJ C Fruchart
Jan 1, 1986·Methods in Enzymology·A V NicholsT A Musliner
Jun 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·P E Fielding, C J Fielding
May 15, 1981·Biochemical and Biophysical Research Communications·A V NicholsP J Blanche
Jan 1, 1994·Pharmacology & Therapeutics·G FranceschiniL Calabresi
Apr 1, 1994·Current Opinion in Lipidology·J R Schultz, E M Rubin
Mar 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·Y HuangG Assmann
Jun 1, 1993·The American Journal of Medicine·D I SilvermanR C Pasternak
Jan 1, 1954·Methods of Biochemical Analysis·O F DE LALLA, J W GOFMAN
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON
May 12, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jesse RissmanAnthony D Wagner
Jun 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Sebastien ApcherRobin Fåhraeus

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.